Showing results (61-70 of 100) with videos related to
Sort By:
Pageof 10
Frontiers in Immunology|November 15, 2021
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical TrialsYimei Que, Menglei Xu, Yanjie Xu, et al.Frontiers in Medicine|May 17, 2024
Case report: Light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapyXiaolu Long, Ning An, Chunhui Li, et al.Journal of Translational Medicine|May 16, 2025
Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myelomaNing An, Juan Li, Pan Luo, et al.Nature Medicine|March 26, 2026
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 studyNing An, Di Wang, Peiling Zhang, et al.Frontiers in Oncology|May 16, 2022
Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case ReportWanying Liu, Chunrui Li, Yang Cao, et al.Clinical Case Reports|January 18, 2024
Upper gastrointestinal tract immune-related adverse events: Two cases of obstructive complications occurred in immune consolidation therapy after sequential chimeric antigen receptor T cell therapy with autologous hematopoietic stem cell transplantation for refractory/relapsed diffuse large B cell lymphomaQi Zhang, Chunrui Li, Yang Cao, et al.Oncotarget|February 18, 2015
Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis proteinChad M McKee, Yunchuan Ding, Jianfeng Zhou, et al.Journal of Hematology & Oncology|October 24, 2018
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myelomaJinhuan Xu, Qiuxiang Wang, Hao Xu, et al.Cellular Oncology (Dordrecht, Netherlands)|April 2, 2024
Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphomaXiangke Xin, Xiaojian Zhu, Yang Yang, et al.Cytotherapy|March 8, 2022
CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantationNan Yan, Na Wang, Gaoxiang Wang, et al.Pageof 10